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Conclusion: Patients with NSTEACS and elevated troponin but without obstructive
CAD, while having low rates of subsequent MI, are still at considerable risk for 1-year
mortality from cardiac and non-cardiac causes. Further data regarding the underlying
etiologies of death in this high-risk cohort will be presented.
TCT-388
A ‘Direct’ Transfer Protocol for Patients with Non ST-Elevation Myocardial
Infarction Reduces Time to Coronary Angiography
Sean Gallagher, Matthew Lovell, Dan Jones, Eileen Ferguson, Zia Buckhoree, Abid
Ahktar, Andrew Wragg, Andrew Archbold, Jain Ajay
London Chest Hospital, London, United Kingdom
Background: Most patients with NSTEMI present to hospitals without angiography
facilities, and so wait as inpatients for transfer to the regional cardiac centre. This care
model has inherent time delays.
Methods: A novel care pathway for managing NSTEMI, known as the Heart Attack
Centre-Extension (HACX), has been investigated. This pathway identifies patients
with NSTEMI by clinical assessment and rapid troponin testing whilst in the
emergency department. Patients with NSTEMI are transferred to the regional centre
within 1 hour without referral. All unstable patients undergo immediate angiography.
Stable patients undergo angiography on the day of admission unless they arrive after
5pm; then angiography is undertaken on the next available routine list. We have
assessed need for angiography and revascularisation in 702 patients (391 before the
HACX (pre-HACX), and 311 treated via the pathway (post-HACX)). We have also
compared waiting times for angiography and length of hospital stay.
Results: 50/311 (80.4%) of HACX patients underwent angiography. 144/250 (57.6%)
were treated with coronary revascularisation (108 (75%) PCI and 36 (25%) CABG).
106/250 (42.4%) were treated with medical therapy alone. NSTE-ACS was the
discharge diagnosis for 75.4% of HACX patients. Median time from admission to
angiography was pre-HAC-X 7.2 days and post HAC-X 1.02 days (p<0.0001) (figure
1). Median length of stay was 9 days pre-HACX and 3 days post-HACX (p<0.0001).
Conclusion: This novel care pathway allows delivery of early angiography to NSTEMI
patients. The pathway allows accurate diagnosis of NSTEMI, and inappropriate
transfers are infrequent.
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Background: Previous studies suggested worse outcomes with primary PCI for
STEMI at US vs OUS sites, but there are little data in pts with NSTEACS.
Methods: ACUITY randomized 13,819 NSTEACS pts in 17 countries to an early
invasive approach with 1 of 3 strategies: 1) heparin plus GPI, 2) bivalirudin (Biv) plus
GPI, or 3) Biv alone.
Results: US pts were heavier, had more HTN, DM, prior MI, prior CABG and anemia.
OUS pts were older, had more renal insufficiency and more positive cardiac markers.
US pts were more often managed with medical therapy and less often with PCI but
had more DES use (83% vs 37%, p<0.0001). US pts received aspirin, statins and beta
blockers more often at admission, but received thienopyridines less often pre-
angiography and at discharge. At 1 yr US pts had lower mortality and lower TVR but
more MI. Bleeding was similar at 30 days. After adjusting for baseline risk, US pts
had more MI but lower TVR with no difference in mortality or MACE.
ACUITY 1 Year Outcomes: US vs OUS
Conclusion: US pts with NSTEACS had higher rates of MI but lower rates of TVR
and no differences in adjusted mortality and bleeding. Lower TVR rates may be related
to greater DES use. Higher rates of MI at US sites may be due to unmeasured
confounders, differences in the threshold for event reporting, or valid differences in
systems of care and treatment which may impact outcomes.
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Background: Appropriate use criteria for coronary revascularization were published
in 2009. While a large national analysis demonstrated low overall rates of inappropriate
revascularization, variability exists among institutions. We sought to determine whether
use of a prospective AUC assessment tool used at the time of procedure would improve
rates of appropriate revascularization.
Methods: A form was designed to be used at the time of diagnostic coronary
angiography. The form includes five key factors: 1) classification of angina severity,
2) level of risk based on non-invasive stress testing, 3) presence of other high risk
markers, 4) number of anti-anginal medications, and 5) coronary anatomy. The first
four to be considered prior to starting the angiogram, so that real-time decision-making
could be made about the appropriateness of revascularization once the coronary
anatomy was known.
Results: Since initiation of the AUC tool in March 2011 at our cardiac center, 216
patients underwent coronary revascularization. For these cases, overall rates of
appropriate (A), uncertain (U), and inappropriate (I) revascularization were 89%, 9%,
and 2%, respectively. Patients with acute coronary syndrome (ACS) (68%) had A, U,
and I scores of 94%, 4% and 2%, respectively. Among those with stable ischemic heart
disease (SIHD), 47% had an intermediate or high-risk noninvasive stress test. There
was infrequent use of >1 anti-anginal medication in all patients (48% in ACS versus
37% in SIHD). Compared to same facility retrospective analysis from the preceding
18 months, inappropriate rates after implementation of the AUC tool dropped from 3%
to 2%.
Conclusion: Symptoms, angina class and stress test findings predominantly drive
revascularization decisions. An unacceptably high number of patients with low risk
stress tests or suboptimal anti-anginal therapy undergo revascularization. Routine use
of our assessment tool allows the appropriateness status to be determined at the time
of procedure and results in a lower rate of inappropriate revascularization.
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